Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae

Chemotherapy
A JacolotOlivier Mimoz

Abstract

The aim of this study was to compare the bactericidal activity of cefepime plus amikacin against experimental pneumonia induced by a stably derepressed cephalosporinase-producing Enterobacter cloacae strain in immunocompetent and leucopenic rats. Sixty Wistar rats were used. Leucopenia was induced in half of them by a single intravenous administration of 30 mg/kg cyclophosphamide, while the remaining rats received the same volume of saline. All rats were infected 96 h later by tracheal instillation of 8 log(10) colony-forming units of E. cloacae. Twelve rats (6 immunocompetent and 6 leucopenic) were sacrificed 6 h later to assess the initial bacterial burden to the lungs. Then, the remaining 48 rats received a combination of 60 mg/kg cefepime twice a day and 25 mg/kg amikacin once a day given intraperitoneally or the same volume of saline. Six rats per group (leucopenic or not, treated or not) were sacrificed 12 and 30 h after therapy started. Spontaneous bacterial clearance with time was observed only in immunocompetent rats. Compared to untreated animals, antibiotic administration induced a decrease in lung bacterial titres in immunocompetent and leucopenic rats. The difference was statistically significant only in leucopenic...Continue Reading

References

Jul 1, 1992·Antimicrobial Agents and Chemotherapy·R H BarbhaiyaK A Pittman
Jul 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Dalhoff, U Ullmann
Jan 1, 1987·Antimicrobial Agents and Chemotherapy·R H BarbhaiyaK A Pittman
Feb 1, 1981·Journal of Pharmaceutical Sciences·K M GiacominiG Levy
Oct 1, 1994·European Journal of Drug Metabolism and Pharmacokinetics·I Mahmood, D H Waters
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·A D KashubaJ S Bertino
Apr 30, 2002·International Journal of Antimicrobial Agents·D Andes, W A Craig
Sep 3, 2002·The Journal of Antimicrobial Chemotherapy·Vincent H TamGeorge L Drusano
Nov 26, 2002·American Journal of Hematology·K TamuraUNKNOWN Kyushu Hematology Organization for Treatment (K-HOT) Study Group
Sep 3, 2003·The Journal of Antimicrobial Chemotherapy·Sheryl A ZelenitskyRobert E Ariano
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Scott T MicekMarin H Kollef
Aug 19, 2007·International Journal of Antimicrobial Agents·Christian van Delden
Nov 8, 2008·Intensive Care Medicine·Antoni TorresUNKNOWN European HAP working group
Nov 26, 2010·Chemotherapy·Anjali N Kunz, Itzhak Brook

❮ Previous
Next ❯

Citations

Jun 25, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Jizhong ZhaoXueyong Shen
Sep 12, 2019·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jeffrey E GottsMichael A Matthay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.